Bill would require lot‑specific infant formula testing and public disclosure; industry urges alternatives

Assemblymember Rodriguez told the Senate Health Committee that AB 2302 aims to give parents, WIC agencies and health providers ready access to lot‑specific test results for arsenic, lead, cadmium, mercury and other contaminants in infant formula.

"Parents deserve confidence that the products they rely on to nourish their infants are subject to rigorous testing and transparent reporting," sponsor Carly Clemens of Children Now told the committee on behalf of the bill’s supporters. WIC representatives and pediatric groups said transparency would rebuild trust after prior recalls and testing campaigns.

Industry witnesses pushed back. Missy Johnson of the Infant Nutrition Council of America said manufacturers already test product and that the FDA recently released a major market‑basket analysis. She and other industry representatives urged either adopting stringent EU numerical limits as a compliance threshold or keeping the regulatory approach narrowly harmonized with federal standards to avoid confusing caregivers or disrupting supply.

"Without providing consumers with more context about the levels and what is considered safe, this data is difficult to understand," the industry witness said, arguing a QR code linking to raw lot numbers could alarm parents without clear interpretation.

Supporters said the bill would follow the model used in prior California testing laws and would allow formats that make results accessible rather than merely dumping numbers online. Opponents proposed a ban‑style alternative (attest to EU limits) but advocates said that solution could weaken transparency and enforcement.

The committee heard competing policy tradeoffs: consumer confidence and accountability versus regulatory complexity, labeling timelines and potential supply‑chain consequences. The author said she would continue negotiating technical amendments to narrow labeling language and data requirements.

Next steps: Committee advanced the discussion; further amendments are expected to refine whether reporting is lot‑specific, the data display format, the role of state review versus industry self‑attestation and the interplay with FDA testing.